FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2527553935> ?p ?o ?g. }

• W2527553935 endingPage "520" @default.
• W2527553935 startingPage "511" @default.
• W2527553935 abstract "Purpose Many technological and methodical advances have made stereotactic body radiotherapy (SBRT) more accurate and more efficient during the last years. This study aims to investigate whether experience in SBRT and technological innovations also translated into improved local control (LC) and overall survival (OS). Methods and Materials A database of 700 patients treated with SBRT for lung metastases in 20 German centers between 1997 and 2014 was used for analysis. It was the aim of this study to investigate the impact of fluorodeoxyglucose positron-emission tomography (FDG-PET) staging, biopsy confirmation, image guidance, immobilization, and dose calculation algorithm, as well as the influence of SBRT experience, on LC and OS. Results Median follow-up time was 14.3 months (range, 0-131.9 months), with 2-year LC and OS of 81.2% (95% confidence interval [CI] 75.8%-85.7%) and 54.4% (95% CI 50.2%-59.0%), respectively. In multivariate analysis, all treatment technologies except FDG-PET staging did not significantly influence outcome. Patients who received pre-SBRT FDG-PET staging showed superior 1- and 2-year OS of 82.7% (95% CI 77.4%-88.6%) and 64.8% (95% CI 57.5%-73.3%), compared with patients without FDG-PET staging resulting in 1- and 2-year OS rates of 72.8% (95% CI 67.4%-78.8%) and 52.6% (95% CI 46.0%-60.4%), respectively (P=.012). Experience with SBRT was identified as the main prognostic factor for LC: institutions with higher SBRT experience (patients treated with SBRT within the last 2 years of the inclusion period) showed superior LC compared with less-experienced centers (P≤.001). Experience with SBRT within the last 2 years was independent from known prognostic factors for LC. Conclusion Investigated technological and methodical advancements other than FDG-PET staging before SBRT did not significantly improve outcome in SBRT for pulmonary metastases. In contrast, LC was superior with increasing SBRT experience of the individual center. Many technological and methodical advances have made stereotactic body radiotherapy (SBRT) more accurate and more efficient during the last years. This study aims to investigate whether experience in SBRT and technological innovations also translated into improved local control (LC) and overall survival (OS). A database of 700 patients treated with SBRT for lung metastases in 20 German centers between 1997 and 2014 was used for analysis. It was the aim of this study to investigate the impact of fluorodeoxyglucose positron-emission tomography (FDG-PET) staging, biopsy confirmation, image guidance, immobilization, and dose calculation algorithm, as well as the influence of SBRT experience, on LC and OS. Median follow-up time was 14.3 months (range, 0-131.9 months), with 2-year LC and OS of 81.2% (95% confidence interval [CI] 75.8%-85.7%) and 54.4% (95% CI 50.2%-59.0%), respectively. In multivariate analysis, all treatment technologies except FDG-PET staging did not significantly influence outcome. Patients who received pre-SBRT FDG-PET staging showed superior 1- and 2-year OS of 82.7% (95% CI 77.4%-88.6%) and 64.8% (95% CI 57.5%-73.3%), compared with patients without FDG-PET staging resulting in 1- and 2-year OS rates of 72.8% (95% CI 67.4%-78.8%) and 52.6% (95% CI 46.0%-60.4%), respectively (P=.012). Experience with SBRT was identified as the main prognostic factor for LC: institutions with higher SBRT experience (patients treated with SBRT within the last 2 years of the inclusion period) showed superior LC compared with less-experienced centers (P≤.001). Experience with SBRT within the last 2 years was independent from known prognostic factors for LC. Investigated technological and methodical advancements other than FDG-PET staging before SBRT did not significantly improve outcome in SBRT for pulmonary metastases. In contrast, LC was superior with increasing SBRT experience of the individual center." @default.
• W2527553935 created "2016-10-07" @default.
• W2527553935 creator A5008555900 @default.
• W2527553935 creator A5010325047 @default.
• W2527553935 creator A5014432039 @default.
• W2527553935 creator A5016393405 @default.
• W2527553935 creator A5023510680 @default.
• W2527553935 creator A5032037681 @default.
• W2527553935 creator A5038338085 @default.
• W2527553935 creator A5039229070 @default.
• W2527553935 creator A5039691793 @default.
• W2527553935 creator A5044179041 @default.
• W2527553935 creator A5046756579 @default.
• W2527553935 creator A5046979273 @default.
• W2527553935 creator A5048585327 @default.
• W2527553935 creator A5053943773 @default.
• W2527553935 creator A5054903967 @default.
• W2527553935 creator A5055289994 @default.
• W2527553935 creator A5059493220 @default.
• W2527553935 creator A5060902751 @default.
• W2527553935 creator A5064008006 @default.
• W2527553935 creator A5067838462 @default.
• W2527553935 creator A5069002225 @default.
• W2527553935 creator A5070051122 @default.
• W2527553935 creator A5072040768 @default.
• W2527553935 creator A5073250102 @default.
• W2527553935 creator A5073682650 @default.
• W2527553935 creator A5079287119 @default.
• W2527553935 date "2017-07-01" @default.
• W2527553935 modified "2023-09-27" @default.
• W2527553935 title "Influence of Institutional Experience and Technological Advances on Outcome of Stereotactic Body Radiation Therapy for Oligometastatic Lung Disease" @default.
• W2527553935 cites W1501578618 @default.
• W2527553935 cites W1965263688 @default.
• W2527553935 cites W1971572535 @default.
• W2527553935 cites W1972037710 @default.
• W2527553935 cites W1977792423 @default.
• W2527553935 cites W1987357850 @default.
• W2527553935 cites W1992092107 @default.
• W2527553935 cites W2015384858 @default.
• W2527553935 cites W2023941884 @default.
• W2527553935 cites W2031688279 @default.
• W2527553935 cites W2031702956 @default.
• W2527553935 cites W2036855640 @default.
• W2527553935 cites W2037407820 @default.
• W2527553935 cites W2044564816 @default.
• W2527553935 cites W2054974480 @default.
• W2527553935 cites W2061285215 @default.
• W2527553935 cites W2100699934 @default.
• W2527553935 cites W2100744367 @default.
• W2527553935 cites W2112097252 @default.
• W2527553935 cites W2134134167 @default.
• W2527553935 cites W2135374201 @default.
• W2527553935 cites W2140057952 @default.
• W2527553935 cites W2145726776 @default.
• W2527553935 cites W2157751183 @default.
• W2527553935 cites W2164600029 @default.
• W2527553935 cites W2166459387 @default.
• W2527553935 cites W2319687260 @default.
• W2527553935 cites W2344871417 @default.
• W2527553935 doi "https://doi.org/10.1016/j.ijrobp.2016.09.026" @default.
• W2527553935 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27843031" @default.
• W2527553935 hasPublicationYear "2017" @default.
• W2527553935 type Work @default.
• W2527553935 sameAs 2527553935 @default.
• W2527553935 citedByCount "37" @default.
• W2527553935 countsByYear W25275539352017 @default.
• W2527553935 countsByYear W25275539352018 @default.
• W2527553935 countsByYear W25275539352019 @default.
• W2527553935 countsByYear W25275539352020 @default.
• W2527553935 countsByYear W25275539352021 @default.
• W2527553935 countsByYear W25275539352022 @default.
• W2527553935 countsByYear W25275539352023 @default.
• W2527553935 crossrefType "journal-article" @default.
• W2527553935 hasAuthorship W2527553935A5008555900 @default.
• W2527553935 hasAuthorship W2527553935A5010325047 @default.
• W2527553935 hasAuthorship W2527553935A5014432039 @default.
• W2527553935 hasAuthorship W2527553935A5016393405 @default.
• W2527553935 hasAuthorship W2527553935A5023510680 @default.
• W2527553935 hasAuthorship W2527553935A5032037681 @default.
• W2527553935 hasAuthorship W2527553935A5038338085 @default.
• W2527553935 hasAuthorship W2527553935A5039229070 @default.
• W2527553935 hasAuthorship W2527553935A5039691793 @default.
• W2527553935 hasAuthorship W2527553935A5044179041 @default.
• W2527553935 hasAuthorship W2527553935A5046756579 @default.
• W2527553935 hasAuthorship W2527553935A5046979273 @default.
• W2527553935 hasAuthorship W2527553935A5048585327 @default.
• W2527553935 hasAuthorship W2527553935A5053943773 @default.
• W2527553935 hasAuthorship W2527553935A5054903967 @default.
• W2527553935 hasAuthorship W2527553935A5055289994 @default.
• W2527553935 hasAuthorship W2527553935A5059493220 @default.
• W2527553935 hasAuthorship W2527553935A5060902751 @default.
• W2527553935 hasAuthorship W2527553935A5064008006 @default.
• W2527553935 hasAuthorship W2527553935A5067838462 @default.
• W2527553935 hasAuthorship W2527553935A5069002225 @default.
• W2527553935 hasAuthorship W2527553935A5070051122 @default.
• W2527553935 hasAuthorship W2527553935A5072040768 @default.
• W2527553935 hasAuthorship W2527553935A5073250102 @default.
• W2527553935 hasAuthorship W2527553935A5073682650 @default.

• next